0
Skip to Content
NMD Pharma
Home
About NMD Pharma
Management team
Our team
Board
Founders
Pipeline
Science
Neuromuscular diseases
Patient insights
Scientific publications
Information for patients
Myasthenia Gravis
Spinal Muscular Atrophy
Charcot-Marie-Tooth
Press releases
Events
Other news
Investors
Your career
Find your job
Contact
NMD Pharma
Home
About NMD Pharma
Management team
Our team
Board
Founders
Pipeline
Science
Neuromuscular diseases
Patient insights
Scientific publications
Information for patients
Myasthenia Gravis
Spinal Muscular Atrophy
Charcot-Marie-Tooth
Press releases
Events
Other news
Investors
Your career
Find your job
Contact
Home
Folder: About
Back
About NMD Pharma
Management team
Our team
Board
Founders
Folder: R&D
Back
Pipeline
Science
Neuromuscular diseases
Patient insights
Scientific publications
Folder: Patients & Clinical Trials
Back
Information for patients
Myasthenia Gravis
Spinal Muscular Atrophy
Charcot-Marie-Tooth
Folder: News
Back
Press releases
Events
Other news
Investors
Folder: Careers
Back
Your career
Find your job
Contact
Press release Stine Krag Brunvold 1/22/24 Press release Stine Krag Brunvold 1/22/24

NMD Pharma Appoints Morten Bull as SVP, General Counsel and Head of People & Business Services

Read More
Press release Stine Krag Brunvold 11/15/23 Press release Stine Krag Brunvold 11/15/23

NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing

Read More
Press release Stine Krag Brunvold 10/3/23 Press release Stine Krag Brunvold 10/3/23

NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society

Read More
Press release Stine Krag Brunvold 9/26/23 Press release Stine Krag Brunvold 9/26/23

NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy

Read More
Press release Stine Krag Brunvold 9/8/23 Press release Stine Krag Brunvold 9/8/23

NMD Pharma to host a Satellite Symposium and present new clinical data at the 148th Annual Meeting of the American Neurological Association

Read More
Press release Stine Krag Brunvold 6/20/23 Press release Stine Krag Brunvold 6/20/23

NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2

Read More
Press release Stine Krag Brunvold 6/9/23 Press release Stine Krag Brunvold 6/9/23

NMD Pharma to Present Results from the Charcot-Marie-Tooth ESTABLISH Study at the Peripheral Nerve Society Annual Meeting

Read More
Press release Stine Krag Brunvold 6/1/23 Press release Stine Krag Brunvold 6/1/23

NMD Pharma appoints Daniel Brennan as SVP, Corporate and Commercial Strategy

Read More
Press release Stine Krag Brunvold 5/23/23 Press release Stine Krag Brunvold 5/23/23

NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343

Read More
Press release Stine Krag Brunvold 1/3/23 Press release Stine Krag Brunvold 1/3/23

Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors

Read More
Press release Stine Krag Brunvold 12/14/22 Press release Stine Krag Brunvold 12/14/22

NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3

Read More
Press release Stine Krag Brunvold 10/11/22 Press release Stine Krag Brunvold 10/11/22

NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis

Read More
Press release Stine Krag Brunvold 9/27/22 Press release Stine Krag Brunvold 9/27/22

FDA grants Orphan Drug Designation for NMD670 for the Treatment of Myasthenia Gravis

Read More
Press release Stine Krag Brunvold 5/10/22 Press release Stine Krag Brunvold 5/10/22

NMD Pharma appoints Dr. Jorge A. Quiroz as EVP, Chief Medical Officer

Read More
Press release Stine Krag Brunvold 5/3/22 Press release Stine Krag Brunvold 5/3/22

NMD Pharma expands its US presence

Read More
Press release Stine Krag Brunvold 2/15/22 Press release Stine Krag Brunvold 2/15/22

NMD Pharma Raises €35 Million in a new Financing

Read More
Press release Stine Krag Brunvold 7/8/21 Press release Stine Krag Brunvold 7/8/21

NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease

Read More
Press release Stine Krag Brunvold 6/30/21 Press release Stine Krag Brunvold 6/30/21

NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670

Read More
Press release Stine Krag Brunvold 6/1/21 Press release Stine Krag Brunvold 6/1/21

NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults

Read More
Press release Stine Krag Brunvold 11/30/20 Press release Stine Krag Brunvold 11/30/20

NMD Pharma Moves Corporate Headquarters to INCUBA to Support Future Growth

It all begins with an idea.

Read More
Newer Posts
Older Posts

NMD PHARMA A/S, CVR No. 36899069

Cookie Policy Terms of Use Privacy Policy US Expanded Access Policy

Follow us
LinkedIn X Facebook Instagram